



Satellite session Sponsored by AstraZeneca

SGLT2 inhibition in heart failure: Recalculating the HF_rEF treatment paradigm

Monday, October 5, 2021- 13:00- 14:00

Opening: **Dr. Avishay Grupper**

The new HF_rEF guidelines- what's new??

Edo Y. Birati, MD FACC

Chief, Cardiovascular Medicine

Poriya Medical Center

Faculty of Medicine, Bar-Ilan University

Optimizing treatment initiation: time and patient profile matters

Avishay Grupper, MD

Heart Failure Institute, Sheba Medical Center

Chairman elect, Heart failure working group, Israeli Heart Society

The correlation and impact of CKD and HF

Michal Laufer-Perl

Director of the cardiovascular clinics

Director of the Heart Failure Service

Tel Aviv Sourasky Medical center

Real world data about interaction of HF medications, and safety of SGLT2i's

Oren Caspi

Director of Heart Failure Unit and the Cardiovascular Research and Innovation Center,

Cardiology,

Rambam Health Care Campus

Panel Discussion: **Dr. Edo Birati**